Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3, East Qingchun Road, 310016, Hangzhou, Zhejiang, China.
Department of Clinical Statistics, 3M China Research and Development Center, Shanghai, China.
Intensive Care Med. 2018 Nov;44(11):1888-1895. doi: 10.1007/s00134-018-5379-2. Epub 2018 Sep 25.
Although sodium bicarbonate (SB) solution has been widely used in clinical practice, its effect on mortality when administered to a large population of patients with acidosis is not known. The study aimed to investigate the effectiveness of SB infusion in septic patients with metabolic acidosis.
Septic patients with metabolic acidosis were identified from the Medical Information Mart for Intensive Care (MIMIC)-III database. Propensity score (PS) was used to account for the baseline differences in the probability to receive SB or not. The marginal structural Cox model (MSCM) was employed to adjust for both baseline and time-varying confounding factors.
A total of 1718 septic patients with metabolic acidosis were enrolled in the study, including 500 in the SB group and 1218 in the non-SB group. Both pH [7.16 (standard deviation (SD): 0.10) vs. 7.22 (SD: 0.07); p < 0.001] and bicarbonate concentration (BC) [11.84 (SD: 3.63) vs. 14.88 (SD: 3.36) mmol/l; p < 0.001] were significantly lower in the SB than that in the non-SB group. While there was no significant mortality effect in the overall population [hazard ratio (HR): 1.04; 95% CI 0.86-1.26; p = 0.67], SB was observed to be beneficial in patients with acute kidney injury (AKI) stage 2 or 3 and pH < 7.2 (HR 0.74; 95% CI 0.51-0.86; p = 0.021). Similar results were replicated with the MSCM.
Our study observed that SB infusion was not associated with improved outcome in septic patients with metabolic acidosis, but it was associated with improved survival in septic patients with AKI stage 2 or 3 and severe acidosis. The results need to be verified in randomized controlled trials.
尽管碳酸氢钠(SB)溶液已在临床实践中广泛应用,但对于酸中毒的大量患者使用 SB 对死亡率的影响尚不清楚。本研究旨在探讨 SB 输注对合并代谢性酸中毒的脓毒症患者的疗效。
从医疗信息监测网络(MIMIC)-III 数据库中确定合并代谢性酸中毒的脓毒症患者。采用倾向评分(PS)来解释接受 SB 或不接受 SB 的概率的基线差异。采用边缘结构 Cox 模型(MSCM)来调整基线和随时间变化的混杂因素。
本研究共纳入 1718 例合并代谢性酸中毒的脓毒症患者,其中 SB 组 500 例,非 SB 组 1218 例。SB 组 pH [7.16(标准差(SD):0.10)比非 SB 组 7.22(SD:0.07);p<0.001]和碳酸氢盐浓度(BC)[11.84(SD:3.63)比非 SB 组 14.88(SD:3.36)mmol/L;p<0.001]均显著降低。虽然在总体人群中死亡率无显著差异[风险比(HR):1.04;95%置信区间(CI)0.86-1.26;p=0.67],但在 AKI 2 或 3 期且 pH<7.2 的患者中,SB 有益(HR 0.74;95%CI 0.51-0.86;p=0.021)。MSCM 也得到了类似的结果。
本研究观察到 SB 输注对合并代谢性酸中毒的脓毒症患者的预后无改善作用,但在 AKI 2 或 3 期且严重酸中毒的脓毒症患者中与生存改善相关。这些结果需要在随机对照试验中验证。